Immix Biopharma Inc. (IMMX)

Immix Biopharma (IMMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Immix Biopharma is a biotech company focused on developing CAR-T and other cell-based therapies for cancers and heme disorders. Their most advanced project is NXC-201, a BCMA-targeted CAR-T natural ki...

Immix Biopharma, Inc. (IMMX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed ...

The FDA clears Immix's (IMMX) investigational new drug application for BCMA CAR-T cell therapy, NXC-201, to expand clinical studies in relapsed/refractory AL amyloidosis to the United States. Stock fa...

Immix Biopharma, Inc. (IMMX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions co...

Immix (IMMX) gets ODD designation in the United States for lead candidate NXC-201 for the treatment of amyloid light chain (AL) Amyloidosis.

In-licensing of NXC-201 transforms Immix into a mid-to-late stage BCMA-targeting CAR-T therapy with a differentiated tolerability profile. First and only CAR-T therapy in clinical development for AL a...

A high-ranking official at the Federal Reserve has indicated that the US central bank is planning to maintain its benchmark interest rate during its September policy meeting. This decision comes in re...

While 2022 has been a terrible year for investors looking for penny stocks to buy, 2023 might not be as bad. The economy went through a choppy year, and particularly volatile assets such as penny stoc...

Hot penny stocks to watch this week. The post Penny Stocks To Buy?